[go: up one dir, main page]

EP0672054A4 - Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine. - Google Patents

Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine.

Info

Publication number
EP0672054A4
EP0672054A4 EP93901575A EP93901575A EP0672054A4 EP 0672054 A4 EP0672054 A4 EP 0672054A4 EP 93901575 A EP93901575 A EP 93901575A EP 93901575 A EP93901575 A EP 93901575A EP 0672054 A4 EP0672054 A4 EP 0672054A4
Authority
EP
European Patent Office
Prior art keywords
biological function
novel molecule
neuropeptide tyrosine
inhibits
inhibits neuropeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901575A
Other languages
German (de)
English (en)
Other versions
EP0672054A1 (fr
Inventor
Albert Tseng
Adam S Inglis
Lisa Selbie
Erica Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Prince of Wales Medical Research Institute Ltd POWMRI
Original Assignee
Garvan Institute of Medical Research
Prince of Wales Medical Research Institute Ltd POWMRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Institute of Medical Research, Prince of Wales Medical Research Institute Ltd POWMRI filed Critical Garvan Institute of Medical Research
Publication of EP0672054A1 publication Critical patent/EP0672054A1/fr
Publication of EP0672054A4 publication Critical patent/EP0672054A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP93901575A 1991-12-19 1992-12-21 Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine. Withdrawn EP0672054A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU106/91 1991-12-19
AUPL010691 1991-12-19
PCT/AU1992/000673 WO1993012139A1 (fr) 1991-12-19 1992-12-21 Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine

Publications (2)

Publication Number Publication Date
EP0672054A1 EP0672054A1 (fr) 1995-09-20
EP0672054A4 true EP0672054A4 (fr) 1996-02-07

Family

ID=3775895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901575A Withdrawn EP0672054A4 (fr) 1991-12-19 1992-12-21 Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine.

Country Status (4)

Country Link
EP (1) EP0672054A4 (fr)
JP (1) JPH08501055A (fr)
CA (1) CA2126212A1 (fr)
WO (1) WO1993012139A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
EP0889034B1 (fr) * 1996-03-21 2003-09-17 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyridine
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP1620091B1 (fr) 2003-05-05 2010-03-31 Probiodrug AG Inhibiteurs de glutaminyl-cyclase
WO2005049027A2 (fr) 2003-11-03 2005-06-02 Probiodrug Ag Combinaisons utiles au traitement de troubles neuronaux
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (fr) 2007-03-01 2013-01-09 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490338A (de) * 1967-04-13 1970-05-15 Ciba Geigy Verfahren zur Herstellung von ACTH-wirksamen Peptiden mit verlängerter Wirkung
EP0225020A2 (fr) * 1985-10-19 1987-06-10 Beecham Group Plc Peptides comprenant dans leur séquence des unités sélectionnées parmi les restes d'acides aminés 17 à 24 du VIP
WO1991008223A1 (fr) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Nouveaux peptides derives du neuropeptide y
WO1993009227A1 (fr) * 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Recepteur de neuropeptide y-y1 humain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
DE3811193A1 (de) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
ATE109979T1 (de) * 1990-03-30 1994-09-15 Heumann Pharma Gmbh & Co Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
SE467340B (sv) * 1990-07-04 1992-07-06 Perstorp Ab Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490338A (de) * 1967-04-13 1970-05-15 Ciba Geigy Verfahren zur Herstellung von ACTH-wirksamen Peptiden mit verlängerter Wirkung
EP0225020A2 (fr) * 1985-10-19 1987-06-10 Beecham Group Plc Peptides comprenant dans leur séquence des unités sélectionnées parmi les restes d'acides aminés 17 à 24 du VIP
WO1991008223A1 (fr) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Nouveaux peptides derives du neuropeptide y
WO1993009227A1 (fr) * 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Recepteur de neuropeptide y-y1 humain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALASUBRAMANIAN, A. ET AL.: "Synthseis and receptor affinities of partial sequences of peptide YY (PYY)", PEPTIDE RESEARCH, vol. 1, no. 1, pages 32 - 35, XP002039197 *
LACOMBE, J.M. ET AL.: "Malaria invasion of human erythrocytes", INT. J. PEPTIDE PROTEIN RES., vol. 32, pages 104 - 116, XP009038013 *
See also references of WO9312139A1 *
SERVIN, A.L. ET AL.: "Peptide-YY and Neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated ...", ENDOCRINOLOGY, vol. 124, no. 2, pages 692 - 700 *

Also Published As

Publication number Publication date
CA2126212A1 (fr) 1993-07-08
EP0672054A1 (fr) 1995-09-20
WO1993012139A1 (fr) 1993-06-24
JPH08501055A (ja) 1996-02-06

Similar Documents

Publication Publication Date Title
EP0672054A4 (fr) Nouvelle molecule inhibant la fonction biologique du neuropeptide tyrosine.
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
OA09816A (en) "Biological control agents".
ZA92908B (en) Compounds.
FI921125A0 (fi) Ciclosporin.
FI953489A0 (fi) 2,6-diaminopuriinijohdannaisia
FI954651A7 (fi) Mahdollisesti substituoidut 6,8-kinoliinit
FI923314L (fi) Substituerade cyklopropylamino-1,3,5-triaziner
MX9204547A (es) Neristatina 1.
DE59204008D1 (en) Trachealstent.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
GB9220658D0 (en) Substituted 2,6-diaminotoluenes
ZA926482B (en) Cyanophenylpyrroles.
DE59202341D1 (de) Taumelpresse.
AU2717992A (en) Compact bar code scanning arrangement
ZA929590B (en) Diphenylsulphides.
ZA917516B (en) Substituted 5-alkoxy-1,2,4-triazol-3-(thi)ones
ZA929724B (en) Ballisitc materials.
MX9202690A (es) Nuevos compuestos de cefem.
DE69203865D1 (en) Thermo-transferdrucksystem.
ZA929820B (en) Heisswinderschieber.
ZA925725B (en) Qinolin-2-yl-methoxybenzylhydroxyureas.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.
ZA942880B (en) 2,6.disubstituted 4-quinolyl-dihydropridines
TR26505A (tr) Fenil ikameli 4,5- dihidropirazoller

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19951227

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960104